MaRS Innovation to commercialize two technologies

MaRS Innovation has announced its first two medical technologies for commercialization. MaRS Innovation — funded through the Centres of Excellence for Commercialization and Research program (R$, October 7/08) — is collaborating with the Samuel Lunenfeld Research Institute (SLRI) to commercialize an umbilical cord stem cell technology to initially treat diabetes and possible cardiovascular disease and neurological disorders The technology was developed by SLRI scientists Dr Ian Rogers and Dr Robert Casper. The second initiative is with the Univ of Toronto to commercialize sustained release formulation of nitric oxide (NO) for applications in wound healing, including diabetic ulcers. U of T scientists Dr Ping lee and Dr Yan Li developed the NO sustained release technology….